Skip to main content

Advertisement

Table 2 Summary of Effectiveness

From: Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

  GEM-E GEM p-valuea
(n = 1,331) (n = 2,936)  
Overall survival time, months
 Mean ± SD 10.48 9.86 0.0977
(325.5 days ± 8.9) (305.6 days ± 5.4)
 Median 6.77 6.68  
(210 days) (207 days)
Overall survival rate per treatment time, %
 6 months 56.5 54.7 0.2108
 12 months 27.0 27.3 0.5988
 24 months 12.9 10.6 0.1350
 36 months 9.3 6.5 0.0977
  1. Abbreviation: GEM Gemcitabine, GEM-E Gemcitabine + Erlotinib
  2. alog-rank test